UNASSIGNED:炎症反应在非肌层浸润性膀胱癌(NMIBC)患者的术后复发中起着潜在的作用。我们的目的是调查血小板与淋巴细胞比率(PLR)平均血小板体积与淋巴细胞比率(MPVLR),和全身免疫炎症指数(SII)在接受常规膀胱内化疗或膀胱内热疗(CHT)治疗的NMIBC中具有预后价值,以及它们之间的差异。
UNASSIGNED:对2016年1月至2020年12月期间接受膀胱内化疗或膀胱内CHT治疗的222例NMIBC患者进行了回顾性队列研究。手术前一周内,PLR,MPVLR,和SII是根据常规血液沉降确定的。使用接收器工作特性曲线确定每个指标的最佳截止值,并相应地对各个组进行了分类。采用Kaplan-Meier生存曲线和Cox回归模型对接受各种治疗的NMIBC患者预后的影响因素进行研究。
未经证实:吉西他滨(GEM)组69例(46.3%)肿瘤复发,其中19例(12.8%)进展为肌层浸润性膀胱癌(MIBC)或有转移,CHT组复发19例(26.0%),进展2例(2.7%)。高架PLR,MPVLR,和SII在GEM组中与较高的复发率相关。同时,PLR和MPVLR是独立危险因素。在CHT组,高PLR和SII与术后复发相关,均无独立危险因素。
未经证实:术前临床炎症指标PLR,SII,MPVLR对膀胱灌注化疗NMIBC患者术后无复发生存期(RFS)有一定的预测价值,而PLR和SII可以预测膀胱灌注化疗NMIBC患者的预后。这表明膀胱内CHT可能通过一些未知的机制影响平均血小板体积对肿瘤生长的影响来阻止肿瘤复发。
UNASSIGNED: The inflammatory response plays a potential role in postoperative recurrence in patients with non-muscular invasive bladder cancer (NMIBC). We aimed to investigate whether platelet-to-lymphocyte ratio (PLR), mean platelet volume to lymphocyte ratio (MPVLR), and the systemic immune-inflammatory index (SII) have prognostic values in NMIBC treated with conventional intravesical chemotherapy or intravesical Chemohyperthermia (CHT) and the differences between them.
UNASSIGNED: A retrospective cohort study was conducted on 222 patients with NMIBC treated with Intravesical Chemotherapy or Intravesical CHT between January 2016 and December 2020. Within a week before surgery, PLR, MPVLR, and SII were determined based on routine blood settling. The optimal cutoff value of each index was determined using the receiver operating characteristic curve, and various groups were categorized accordingly. The factors influencing the prognosis of NMIBC patients receiving various treatments were investigated using the Kaplan- Meier survival curve and the Cox regression model.
UNASSIGNED: 69 cases (46.3%) in the gemcitabine (GEM) group had tumor recurrence and 19 (12.8%) of them progressed to muscle-invasive bladder cancer (MIBC) or got metastasis, while 19 cases (26.0%) in the CHT group recurred and 2 (2.7%) progressed. Elevated PLR, MPVLR, and SII were associated with higher recurrence rates in the GEM group. Meanwhile, PLR and MPVLR were the independent risk factors. While in the CHT group, high PLR and SII were related to postoperative recurrence and none of them were independent risk factors.
UNASSIGNED: The preoperative clinical inflammatory indexes PLR, SII, and MPVLR have certain predictive value for the postoperative recurrence-free survival (RFS) in NMIBC patients treated with intravesical chemotherapy while PLR and SII can predict the prognosis of NMIBC patients treated with intravesical CHT, which indicates that intravesical CHT may stop tumor recurrence by influencing the effect of mean platelet volume on tumor growth through some unknown mechanisms.